Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chimerix, a biotechnology company, has completed a single and multi-dose Phase I study of CMX001 in healthy volunteers. This study supports the further development of the drug for multiple dsDNA infections. The company has also initiated the first Phase II multi-dose clinical trial in patients.
Subscribe to our email newsletter
The first Phase II trial will study the effects of multiple doses of CMX001 given to stem cell and kidney transplant recipients with BK viruria. Further studies are planned to explore the ability of CMX001 to prevent cytomegalovirus disease.
CMX001 is being developed for the treatment of smallpox infection and other double stranded DNA virus infections that cause significant human morbidity and mortality.
George Painter, president and CEO of Chimerix, said: “The safety and high oral availability demonstrated by CMX001 in the Phase I trial has exceeded our original expectations. We believe that CMX001 has potential for prevention and treatment of many serious and potentially fatal infections such as smallpox, cytomegalovirus, BK virus and adenovirus.”